94 related articles for article (PubMed ID: 1384452)
1. Calcium channel modulators and susceptibility to ischaemic ventricular fibrillation: modification of cellular calcium overload.
Timour Q; Larbre JP; Kioueh I; Aupetit JF; Loufoua-Moundanga J; Vialle A; Faucon G
Arch Int Pharmacodyn Ther; 1992; 315():30-46. PubMed ID: 1384452
[TBL] [Abstract][Full Text] [Related]
2. [Value of calcium channel blockers in the prevention of ventricular fibrillation of ischemic etiology: experimental arguments].
Timour Q; Freysz M; Aupetit JF; Loufoua J; Frassati D; Faucon G
Bull Acad Natl Med; 1996 Jan; 180(1):215-26; discussion 226-7. PubMed ID: 8696877
[TBL] [Abstract][Full Text] [Related]
3. Disappearance with ischaemic depolarization of the antifibrillatory activity in a sodium channel blocker and appearance in calcium channel blocker.
Bui-Xuan B; Aupetit JF; Freysz M; Loufoua-Moundanga J; Faucon G; Timour Q
Arch Int Pharmacodyn Ther; 1996; 331(3):246-62. PubMed ID: 9124997
[TBL] [Abstract][Full Text] [Related]
4. Ischaemia-induced loss or reversal of the effects of the class I antiarrhythmic drugs on vulnerability to fibrillation.
Aupetit JF; Loufoua-Moundanga J; Faucon G; Timour Q
Br J Pharmacol; 1997 Feb; 120(3):523-9. PubMed ID: 9031759
[TBL] [Abstract][Full Text] [Related]
5. Possible prevention by amlodipine of ventricular fibrillation related to brief ischemia episodes.
Timour Q; Aupetit JF; Freysz M; Frassati D; Faucon G
Can J Physiol Pharmacol; 1996 Dec; 74(12):1308-14. PubMed ID: 9047040
[TBL] [Abstract][Full Text] [Related]
6. Vulnerability to ventricular fibrillation related to ischaemia: comparison of the acute effects of beta-blockers and calcium antagonists.
Aupetit JF; Timour Q; Freysz M; Loufoua-Moundanga J; Omar S; Chevrel G; Faucon G
Arch Int Pharmacodyn Ther; 1994; 327(1):25-39. PubMed ID: 7944825
[TBL] [Abstract][Full Text] [Related]
7. Opposite change with ischaemia in the antifibrillatory effects of class I and class IV antiarrhythmic drugs resulting from the alteration in ion transmembrane exchanges related to depolarization.
Aupetit JF; Bui-Xuan B; Kioueh I; Loufoua J; Frassati D; Timour Q
Can J Physiol Pharmacol; 2000 Mar; 78(3):208-16. PubMed ID: 10721812
[TBL] [Abstract][Full Text] [Related]
8. Prevention by calcium antagonists of profibrillatory effects of class I antiarrhythmic drugs in acute myocardial ischemia: study in pig heart in situ.
Bui-Xuan B; Aupetit JF; Freysz M; Faucon G; Timour Q
Pharmacotherapy; 1997; 17(4):737-45. PubMed ID: 9250551
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of the ischaemia-induced fall of electrical ventricular fibrillation threshold by a calcium antagonist, diltiazem.
Aupetit JF; Timour Q; Chevrel G; Loufoua-Moundanga J; Omar S; Faucon G
Naunyn Schmiedebergs Arch Pharmacol; 1993 Nov; 348(5):509-14. PubMed ID: 8114951
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the in vitro and in vivo cardiovascular effects of two structurally distinct Ca++ channel activators, BAY K 8644 and FPL 64176.
Rampe D; Anderson B; Rapien-Pryor V; Li T; Dage RC
J Pharmacol Exp Ther; 1993 Jun; 265(3):1125-30. PubMed ID: 7685384
[TBL] [Abstract][Full Text] [Related]
11. Effect of calcium channel antagonists on susceptibility to sudden cardiac death: protection from ventricular fibrillation.
Billman GE
J Pharmacol Exp Ther; 1989 Mar; 248(3):1334-42. PubMed ID: 2467981
[TBL] [Abstract][Full Text] [Related]
12. Anti-ischemic and vasorelaxant effects of the new benzazepine calcium channel blocker SQ 31,765.
Grover GJ; Parham CS; Sleph PG; Moreland S
J Pharmacol Exp Ther; 1989 Dec; 251(3):1020-5. PubMed ID: 2481028
[TBL] [Abstract][Full Text] [Related]
13. Effects of diltiazem upon experimental ventricular dysrhythmias.
Patterson E; Eller BT; Lucchesi BR
J Pharmacol Exp Ther; 1983 Apr; 225(1):224-33. PubMed ID: 6834274
[TBL] [Abstract][Full Text] [Related]
14. Influence of nifedipine, verapamil and diltiazem on pulmonary vascular resistance and vasoconstrictors in cats.
Erdemli O; Hao Q; Cai B; Lippton HL; Hyman A
Arch Int Pharmacodyn Ther; 1994; 328(2):165-79. PubMed ID: 7535994
[TBL] [Abstract][Full Text] [Related]
15. Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists.
Zahradníková A; Minarovic I; Zahradník I
J Pharmacol Exp Ther; 2007 Aug; 322(2):638-45. PubMed ID: 17475903
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a beta-adrenergic receptor antagonist, propranolol, in preventing ischaemic ventricular fibrillation: dependence on heart rate and ischaemia duration.
Aupetit JF; Frassati D; Bui-Xuan B; Freysz M; Faucon G; Timour Q
Cardiovasc Res; 1998 Mar; 37(3):646-55. PubMed ID: 9659448
[TBL] [Abstract][Full Text] [Related]
17. Different interaction of bepridil and diltiazem with BAY K 8644 in the abolition of autoregulation of renal blood flow.
Ogawa N; Yokota S; Ono H
J Cardiovasc Pharmacol; 1988 Feb; 11(2):147-50. PubMed ID: 2452307
[TBL] [Abstract][Full Text] [Related]
18. Effect of the Ca(2+)-channel agonist Bay K 8644 on the contractile responses in human placental veins.
Barrús MT; Reviriego J; Marín J
J Auton Pharmacol; 1996 Jun; 16(3):161-7. PubMed ID: 8884463
[TBL] [Abstract][Full Text] [Related]
19. Differential roles of myocardial Ca2+ channels and Na+/Ca2+ exchange in myocardial reperfusion injury in open chest dogs: relative roles during ischemia and reperfusion.
Smart SC; Sagar KB; Warltier DC
Cardiovasc Res; 1997 Dec; 36(3):337-46. PubMed ID: 9534854
[TBL] [Abstract][Full Text] [Related]
20. Influence of dihydropyridine-type calcium agonists on hemodynamics and myocardial ischemia in isolated rabbit hearts.
Rump AF; Rösen R; Sigmund B; Fuchs J; Ratke R; Klaus W
Arzneimittelforschung; 1993 Oct; 43(10):1056-9. PubMed ID: 7505584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
